Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors

01 Nov 2019

AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.

Pebble tower on the seaside - Image — AbbVie is successfully balancing Humira's biosimilar erosion with new brand growth

Third quarter 2019 was one of balance for AbbVie Inc. as a continued strong launch for Skyrizi, good early uptake of Rinvoq, ongoing US sales growth for Humira and steadily rising sales for its hematological cancer franchise offset Humira’s revenue decline in Europe due to biosimilar competition.

The Chicago-area firm reported quarterly net revenues of $8.5bn on 1 November, up 3% year-over-year, as its two new immunology...